Medgenics, Inc. (MDGN) Reports EPODURE to Be Presented at American Society of Nephrology’s Kidney Week 2012Source: http://blog.qualitystocks.net/qualitystocks-stock-newsletters/medgenics-inc-mdgn-reports-epodure-to-be-presented-at-american-society-of-nephrologys-kidney-week-2012/
Posted on Tuesday, October 23rd, 2012 | In Small & Micro Cap
Medgenics is a clinical-stage biopharmaceutical company that is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own tissue for the treatment of a range of chronic diseases. These diseases include anemia, hepatitis, and hemophilia, among others.
The company announced today that it will be presenting a poster at the upcoming American Society of Nephrology’s Kidney Week 2012, taking place in San Francisco from October 30 to November 4. The poster is titled “Novel Sustained delivery of Erythropoietin in Hemodialysis Patients for Safer Anemia Control Using EPODURE Biopumps – Autologous Dermal Tissue Samples Secreting Erythropoitein.”
The poster will present preliminary data from a Phase IIa clinical trial of EPODURE to treat anemia patients with end stage renal disease. EPODURE is an autologous dermal Biopump, implanted subcutaneously, capable of the sustained secretion of therapeutic erythropoitein (EPO) in the body using a small tissue explant from the patient’s own skin and processed to continuously produce EPO for many months.
Medgenics poster will actually be presented on Friday, November 2. It aims to bring this Biopump and others to market via strategic partnerships with major pharmaceutical and medical device companies.
For additional information about Medgenics and its proprietary Biopump technology, please visit www.medgenics.com
Let us hear your thoughts below:
About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net